MS drug Tecfidera approved, awaited


The approval of Biogen Idec's MS therapy Tecfidera follows months of breathless Wall Street hype, and it looks like doctors are psyched for the drug, too. In a MedLIVE PULSE survey conducted by WorldOne Interactive, 40% of U.S neurologists polled said they're currently warehousing patients in anticipation of the new multiple sclerosis drug.